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ABSTRACT 
 
MARKOV DECISION PROCESS APPROACH TO STRATEGIZE NATIONAL BREAST 
CANCER SCREENING POLICY IN DATA-LIMITED SETTINGS 
SEPTEMBER 2019 
VIJETA DESHPANDE,  
B.E. UNIVERSITY OF PUNE, 
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Chaitra Gopalappa 
 
Rising rates of cancer incidence and mortalities in low and middle-income countries 
(LMICs) are burdening the already strained health care systems in LMICs. As cancer rates 
are expected to continue to rise, to better cope with this rapidly changing landscape, 
countries are working on incorporating cancer control programs, including early detection, 
as part of their national strategic planning. In the absence of control programs, cancers 
mostly get diagnosed in the advanced stages when they become symptomatic. While 
treatment in early stages of cancer are mostly effective, treatment in advanced stages is 
complex, expensive and mostly ineffective. Therefore, early diagnosis is a promising 
strategy to reduce premature mortalities and for optimal use of resources. But the absence 
of mathematical models specific to the data settings in LMIC’s impedes the construction 
of economic analysis necessary for decision-makers in the development of cancer control 
programs. This thesis presents a new methodology for parameterizing the natural history 
model of breast cancer based on data availabilities in low and middle income countries, 
 vii 
and formulation of a control optimization problem to find the optimal screening schedule 
for mammography screening, solved using dynamic programming. As harms and benefits 
are known to increase with the increase in the number of lifetime screens, the trade-off was 
modeled by formulating the immediate reward as a function of false positives and life-
years saved. The method presented in thesis will provide optimal screening schedules for 
multiple scenarios of Willingness to Pay (numeric value assigned for each life-year lived), 
including the resulting total number of lifetime screens per person, which can help 
decision-makers evaluate current resource availabilities or plan future resource needs for 
implementation. 
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
 
1.1 Cancer trends and burden in low and middle-income countries 
 
Twenty years ago, communicable diseases such as HIV, malaria and tuberculosis were the 
primary concerns for low and middle-income countries (LMICs) and non-communicable 
diseases (NCDs) such as chronic heart and respiratory diseases, diabetes, and cancers, had 
negligible if any spotlight in overall disease burden in LMICs (1). But from 1990 to 2010, 
cancer fatality in LMICs increased to 7.98 million in 2010, compared to the previous 
decade, is was a 38% increase in cancer-related deaths in LMIC, which constituted a 15.1% 
portion of all global deaths in 2010 (1). Also, newly reported cancer cases in LMICs 
increased from 15% in 1970 to 56% in 2008, and such incremental trends are expected to 
continue to an estimated 70% by 2030 (1) (2). These increases are generating tremendous 
burdens on health care systems. Also, more than 60% of cancer related deaths occurred in 
LMIC and only 5% of global health resources for cancer are spent there (1) (2) (3). Hence, 
it is essential than ever to develop cost effective cancer control strategies specific to LMIC. 
The general recommended approach to cancer control, based on cost-effectiveness 
estimates, is to first prevent the cancers which can be prevented, second, to treat the cancers 
which can be cured and third, to palliate the cancer when the first two approaches fail (1). 
Prevention programs have high potential to reduce the incidence of cancer by 33-50% (1). 
For several cancers, life can be considerably extended with low-cost drug treatment, e.g. 
pancreatic and lung cancer. When treatment is not always a feasible option, palliation 
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through reduction in pain and suffering is deliverable in low cost (3). But many cancers 
out of all those which are responsible for the most burden on LMIC health system are 
amenable to treatment e.g. colorectal cancer, cervical cancer and breast cancer (2).  
Among all cancers, the highest disease burden in women is from breast cancer (4). Global 
breast cancer incidence in 2012 (43.3 per 100,000) was estimated to be 3 times that of the 
next most common cancers in women, namely, colorectal cancer, lung cancer, and cervical 
cancer with 14.3, 13.6, and 14.0 cases, respectively, per 100,000 persons (4). East and 
Central Asia reported the highest proportion of global breast cancer burden, about 36.3% 
and 41.5% of recorded incidence and deaths, respectively (4). Latin America and the 
Caribbean experienced 9.1% cases and 8.3% deaths of the global count (4). 
The population attributable factor (PAF), defined as the contribution of a risk factor to a 
disease or a death, of breast cancer is 27% for high-income countries and 18% for low 
middle-income countries (5). Solin et. al. (6), present results on selective screening 
(according to risk factors such as previous breast biopsy and family history of breast 
cancer) for breast cancer. In the simulation of screening of 17,543 women, more than 50% 
of the cases would not have been detected if it was a selective screening. Madigan et.al. (7) 
and De Waard et.al. (8) present evidence for the fact that only small proportion of the total 
breast cancer cases are related to the known risk parameters for breast cancer. Evidence 
collected from above mentioned studies argues that the sub-setting of women population 
based on the known risk-factors of breast cancer will not successfully identify the target 
group for mammography screening. On the other hand, cancer control largely depends on 
early detection due to the morbid, expensive and often ineffective nature of treatment in 
advanced stages of cancer (9). Hence, given that there are less known attributable risk 
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factors for breast cancer, the next best strategy for breast cancer control is conducting 
mammography screening programs with age-based invitation (4). 
1.2 Screening programs and practices in high-income countries and low and middle-
income countries 
 
Screening programs can either be organized or opportunistic. Organized screening 
programs are those which does have clear invitation protocol to a well-defined target 
population, systematic call and recall for screening, investigation of results, follow-up 
treatments, quality tracking and program database (4). Dissemination of tracking and 
investigating team is also a trait of organized screening programs. Opportunistic programs 
do not target any subset of population but work with recommendations from regular health 
check-ups, therefore dependent on primary health care providers. Organized programs are 
generally evident in high income countries and opportunistic programs in low income 
countries. 
Most of the organized programs for breast cancer approximately target the population in 
age group 40-74 years with biennial frequency of screening (4) (10). But this screening 
schedule greatly depend on the demographics and the epidemics specific to the population. 
Some high-income countries recommend populations in the younger age-group than 50 
years of age for screening while others do not. While screening in age group 50-69 is 
strongly recommended for high-income countries by WHO recommendations, invitation 
to women in age-group 40-49 for mammography screening is conditional (11). For low-
middle income countries, WHO recommends not to screen women in age group 40-49 and 
screening in age group 50-69 is conditional upon the scale and scope of the healthcare 
systems. 
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The next sub sections will briefly discuss the practices in different high and low-middle 
income countries and will point towards the observed positive outcomes of screening 
programs in high-income countries and the discrepancies between the WHO recommended 
guidelines and the current practices in low-middle income countries. 
1.2.1 Practices in high-income countries and outcomes 
 
Countries such as United States, United Kingdom, Finland, Netherland, Canada have 
achieved established (approximately 25 years old) organized breast cancer screening 
programs. In 2007, 26 of the 27 members of states in European Union (former) had an 
active breast cancer screening program, out of which 22 were organized. Seventy nine 
percent of the eligible population in these 26 countries were covered under regular 
screening (mammography) programs, most of the screened population was covered with 
no or little cost for women undergoing screening. All of the countries in EU recommend 
screening for women in age group 50 to 59 years, some countries additionally recommend 
40 to 49 and/or up to 74 years of age. The frequency of screening is biennial for all the 
countries but UK and Malta, while in Austria, yearly screenings are also evident (4). In the 
case of Canada, all provinces have organized screening programs but Nunavut. British 
Columbia started the program in 1988 while Northwest territories started their program in 
2003. Opportunistic screenings are available in those facilities which are not included in 
the organized screening program. All provinces and territories in Canada recommend 
women in age-group 50-69 for biennial screening and similar to EU selective screening for 
women under 50 years of age and over 70 is also available on basis of recommendations 
from practitioners (4). In the USA, promotion of mammography screening started in late 
1980s and early 1990s. Since 1991, biennial screening was recommended and covered in 
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Medicare insurance plan. Private insurances covered mammography screening costs fully. 
The proportion of population not covered in Medicare and private insurance plans faced 
financial barrier for screening, but most of the issues, not all, in these barriers were resolved 
by the introduction of the Affordable Care Act(ACA) (4).  
In these high-income countries, incidence of breast cancer sharply increased from 1980 to 
2000 and mortality rates decreased consistently between 1990 to 2010 (12). Both the 
outcomes are majorly related to increasing prevalence of mammography screening from 
1980 to 2005 (12). An estimated 28% to 65% reduction in mortality rates is expected to 
have occurred because of early detection and the rest proportion due to the systematic 
treatment (13). (Variability in the estimates of different models is associated with the 
difference in the modeling approach and assumptions.) 
1.2.2 Practices in low and middle-income countries 
 
Unlike in high-income countries, screening programs in low and middle-income countries 
have not yet reached to the scale where it can be considered as an organized program. Some 
countries in Asia, such as China and Indonesia, have local community-based screening 
programs (4). In the case of India, screening programs are restricted to controlled study 
purposes only, but educational/awareness programs are promoted (not specific to breast 
cancer) widely (4). Except South Africa, none of the countries in the Sub-Saharan African 
region have developed any screening guidelines for the population. Participation in 
screening programs of breast cancer in South Africa is also very low, approximately 15% 
of women reported having at least one mammogram in lifetime (4). In Central and West 
Asia and North Africa, most of the countries are categorized as low and middle income, in 
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these countries resource allocated to healthcare is limited and screening is rarely available 
(4).  
Latin American countries have increased awareness towards the changing epidemiology of 
cancer and most of the countries where breast cancer is the leading cause of death, have 
developed screening guidelines for population. Most of the countries recommend self and 
clinical breast examination along with mammography for screening (4). Screening 
recommendations in most Latin American countries is for age-group 50-70, along with self 
or clinical examination for the younger age-groups. In few Latin-American countries, 
screening recommendation for women in age-groups 40-49 years is conditioned on breast 
cancer history while for few others, it is unconditioned(4) (14). But the opportunistic or 
regional organized screening programs inspired from such recommendation in Latin-
American countries have not produced the similar reduction in the mortality rates as 
observed in high-income countries (9). 
WHO Position Paper on Mammography Screening (11), recommends screening only for 
those lower-middle income countries which does have strong health systems, i.e. health 
systems having capacity to gradually develop and sustain an organized screening program. 
Recommended guidelines suggest conditional screening for age-group 50-69 and 
guidelines strongly recommends against screening the age-group 40-49 (11). However, 
certain countries such as Peru, a lower middle-income country, has developed legislative 
framework for early diagnosis, treatment and follow-up in 2008 which includes screening 
for women aged 40 years and older (15). The current evidence-based recommendations 
and practices of screening in low-middle income settings greatly vary. Majority of the 
evidence provided for development of the guidelines are either synthesized from the data 
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from randomized control trials conducted in high-income countries or extrapolation of the 
modeling studies conducted for high-income countries (11).  
Therefore, it is essential to inform the development of the screening programs with 
evidence collected from studies which extensively and exclusively consider all aspects of 
the low-middle income settings. 
1.3 Global action plan for non-communicable diseases (NCDs) 
 
In 2008, 63% of the global deaths occurred due to NCDs out of which 38% were premature 
(before the age 70) and 90% of the premature deaths occurred in low and middle-income 
countries. Considering the changing trends and shifting burden of NCDs towards low and 
middle-income settings, the 66th World Health Assembly endorsed the global action plan 
proposed by World Health Organization for prevention and control of NCDs. The goal of 
the Global Action Plan is to reduce the burden in the form of morbidity, mortality and 
disability due to non-communicable diseases, through collaboration at regional, national 
and global level, so that populations will reach the highest attainable levels of health and 
productivity, ensuring the socioeconomic growth. The global action plan offers a paradigm 
shift by providing a road map and a menu of policy options for UN Member States, WHO, 
other UN organizations and intergovernmental organizations, NGOs and the private sector 
which, when implemented collectively between 2013 and 2020, will attain 9 voluntary 
global targets, including a 25% relative reduction in premature mortality from NCDs by 
2025 (16). 
1.4 Intrinsic challenges in mammography screening 
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As stated before, screening programs have resulted in reduction of mortality rates in high-
income countries. When a screening program is organized, even though asymptomatic 
patients benefit from it, a large proportion of the screened population do not experience 
any benefit from screening, which encourages the questions of resource (screening 
resource with auxiliary support staff) management, utilization improvement and target 
group selection. In the case of breast cancer, as it is difficult to determine target group with 
currently known risk factors (5), resource management is a challenging task. 
When a large proportion of screened population is not benefitting from the screening, 
ideally, they also should not experience any harms from it. In fact, screened population 
might be exposed to addition health risks or even death as a result of screening (17) . Some 
health risks are embarked upon screened person with the false positive result of the test, 
which are followed up with more clinical procedures and also causes short term 
psychological distress (4). Other health risks are due to diagnosis of cancer which never 
would have caused death or any degradation of quality of life (17) . There is sufficient 
evidence that women in age group 50-69 are diagnosed with cancer which never would 
have been diagnosed or caused any harms if the women had not been screened (4). In other 
words, when woman undergoes screening she reduces the risk of death due to cancer but 
also accepts the risk of over diagnosis and overtreatment, hence, assessment of risks and 
benefits is of significance. There is sufficient evidence that mammography screening is 
cost effective in the 50-69 age group in the population with high incidence but, importantly, 
there is limited evidence available for cost-effectiveness of the mammography screening 
in low and middle-income settings, as the incidence of cancer in such settings is relatively 
low (4). 
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Considering the fact that mammography screening does have risks along with benefits and 
the necessity of strengthening and orientating health systems towards NCDs, it is required 
to test the validity of mammography in low and middle-income settings and produce 
enough evidence for development of policy menu from which guidelines can be adopted 
to achieve goals mentioned in Global Action Plan. Critically analyzing the balance of 
benefits and risks for producing an age-based invitation policy is a complex decision 
problem, but operations research tools have been successful in developing solutions with 
required cost-benefit balance. Next section will discuss the literature addressing the 
screening decision problems with different operations research tools in different 
perspectives. 
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CHAPTER 2 
LITERATURE REVIEW 
 
In introduction section we discussed the broader challenges faced healthcare systems in 
low and middle-income settings, i.e. changing trends of cancer and lack of resources to 
address increasing incidence and mortality of cancer. In addition to the broader challenges, 
intervention strategies might also have intrinsic complexities in terms of application or 
health risks; e.g. mammography can lead to overdiagnosis and overtreatment. Operations 
Research tools have been successful in performing cost-effective and cost-benefit analysis 
of different intervention strategies for cancer prevention and control. 
2.1 Simulation methods 
 
Simulation models have proven to be an effective tool in testing and/or comparing cost-
effectiveness of different strategies available for decision maker. While simulations models 
can be classified on numerous categories, one important distinction for the models is 
whether the model is empirically based shallow model or biologically based deep model 
(18). Stage shift model, an example of shallow model, simulate the diagnosis events in 
process of comparing the cost-effectiveness of different strategies, e.g. in comparison to 
no screening a specific screening strategy can result into diagnosis in less advance stage or 
early diagnosis in the same stage. But stage shift models do not delineate the trajectory 
followed in result of any specific event, therefore cannot be inclusive of the small details, 
e.g. if diagnosis is a case of overdiagnosis then the resulting life years saved should not be 
considered in the benefits of the strategy, but stage shift cannot incorporate such details 
(18). Opposed to shallow models, deep models are biologically inspired models where the 
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underlying process of leading to results is considered, e.g. the natural progression of tumor. 
As deep models are generally much more detailed than a shallow model, time required for 
their development and data required to tune the parameters is higher than shallow models. 
The comprehensive nature of the deep models also makes them adaptable to the changes 
and therefore can address broader policy question (18). 
Stout et. al. (19), presents a model which evaluates lifetime cost and number of QALY for 
women aged 40 years or older, in the period of 1990 to 2000, for different breast cancer 
screening scenarios. Datum scenario was a one with no screening and other 65 scenarios 
were compared with datum. Out of 65 other scenarios, 64 were designed with different 
variations of starting age, ending age and frequency of screening, and one scenario was 
screening which actually took place from 1990 to 2000 in the USA. Authors found 11 
strategies on the efficient frontier and the annual screening strategy from 40 to 70 years of 
age (closely resembling with the contemporary practices) was one of them with the highest 
cost. Therefore, this study with use of deep model presents alternative strategies which can 
be adopted with lower costs. 
Study report from U.S. Preventive Services Task Force (20), also presents comparative 
analysis of 20 different screening schedules based on benefits (life years gained), resource 
usage (number of mammograms) and harms (false positive rate, unnecessary biopsies and 
overdiagnosis). Results from 6 independently developed models; deep models, developed 
with common input data on incidence, mortality, treatment algorithm and few model 
specific data variables; were compared on the metrics mentioned above. Population 
considered in the models is the cohort of women born in 1960 and tracked from age 25 
years for their whole life. Results indicated that the policies which suggested screening in 
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age group 40-49 had relatively higher harms than the policies which did not include this 
specific age group. In resulting 8 non-dominant strategies out of the total 20 screening 
schedules, 6 schedules started from age 50 and all but one schedule was biennial. Hence, 
this study also presented cost-effectiveness analysis which provided a quantitative 
comparison of different screening policies with help of deep model. 
2.2 Markov Decision Process 
 
Özekici and Pliska (21), by assuming the disease risk and test properties are stationary, 
develop an infinite horizon MDP model minimizing the cost of inspection, false positives, 
treatment and death. They present a policy to screen, for a person whose terminal medical 
care costs and dollar value assigned to each loss of life is higher than 55000 USD. Maillart 
et. al. (22), considering age specific risk and imperfect tests (false-positive/negative), they 
present POMDP model maximizing the probability of survival to investigate screening 
frequency of breast cancer for premenopausal and postmenopausal women. Ayer et. al. 
(23), formulate a finite-horizon POMDP model maximizing the QALY lived during a 
lifespan. They have considered age-dependent disease progression, test accuracies and 
probability of self-detection and show that the individualized personal screening schedules 
resulted into higher QALY than the screening guidelines, simultaneously decreasing the 
total number of mammograms. 
Kong and Mondschein (24), develop a stochastic dynamic programming approach in finite 
planning horizon, minimizing the total expected lifetime cost they determine 
individualized mammography guidelines which will enable dynamic tracking of patient’s 
risk factor. As the optimal policy generated by their model is very aggressive for low-risk 
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patient while is very conservative for high-risk patients, they also suggest segmenting the 
population according to the breast cancer risk for better tracking of risk factors and better 
policy results. Kong et. al. (25) used the same model to present and analyze mammography 
screening policy for Chilean population. 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
CHAPTER 3 
MOTIVATION 
 
Although randomized control trials provide evidence regarding efficacy of the screening 
methods, the stringent barriers on timeline of the study, population under consideration and 
type of screening technology being evaluated in the trial makes usability of the evidence 
limited (18). Trials cannot determine whether the evidence collected with the current cohort 
will also hold for another (18). Also, the screening and follow-up schedule which have 
been followed throughout the trial also needs to be compared with multiple other schedules 
for testing the effectiveness and finding the non-dominant strategies (18). Lastly, the 
decision regarding development of the screening guidelines cannot wait until the 
completion of any specific trial (18). Modeling techniques can leverage findings from trials 
and generate more comprehensive cost-benefit analysis of the screening schedule which 
are of interest to decision maker but are not covered in randomized trials. Furthermore, 
given the current developments in screening technologies, treatment and understanding of 
the disease, finding optimal screening strategy for any population is a moving target 
problem (18), which motivates the development of more flexible models acceptable to the 
current developments and are designed specifically for different population settings. 
Developed models till now are suited to the data availability in high-income countries 
(HIC), while data availability and data quality in LMICs are low, even today. General 
approach used to address LMIC conditions was to extrapolate evidence from models 
developed for HIC. The models which were developed for LMICs, lacked technical depth 
(26) (17). Hence, it is utmost important to develop mathematical models encapsulating 
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epidemics and demographics specific to LMICs while considering the constraints on data 
availability, data quality and healthcare-resources to address the worsening incidence and 
mortality of cancer. 
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CHAPTER 4 
RESEARCH QUESTION 
 
In the background section we discussed how cancer is imparting incremental burden on 
health systems in low-middle income countries due increasing incidence and mortality of 
cancer. We also discussed the different aspects of the cancer control problem, to 
summarize, 
1. In spite of the drastic increase in the incidence and mortality, healthcare system’s 
spending and orientation of control policies towards cancer has not increased in 
low-middle income countries. 
2. Out of all the cancer, burden is mostly imparted due to cancers amenable to 
treatment, i.e. breast cancer, colorectal cancer and cervical cancer. As treatment of 
cancer is morbid, expensive and often ineffective in advanced stages, cancer control 
hinge on early diagnosis. 
3. Moreover, breast cancer incidence in women is thrice the incidence of next most 
common cancers. 
4. Due to low Population Attributable Factor (PAF), breast cancer cannot be 
effectively prevented and population sub-setting for better utilization of screening 
resource is also not possible. Therefore, age-based screening becomes next best 
strategy for breast cancer control. 
5. Guidelines by WHO and practices observed in low-middle income countries do not 
show consensus on schedules of age-based mammography screening. 
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6. Evidence of effectiveness of mammography screening specific to population in 
low-middle income setting is absent and decision making in such setting greatly 
depend upon data from trials conducted in high-income countries or modeling 
studies done specific to high-income setting population. 
Considering all the challenges mentioned above, in this thesis we have considered the case 
of breast cancer in lower-middle income population setting. Following this selection of 
problem, we will present a methodology to address the question of cost-effective age-based 
breast cancer screening schedule for a lower-middle income country for different values of 
willingness to pay of service provider (USD amount assigned to each life year lived), i.e.,  
“What is cost-effective mammography screening schedules specific to a population for 
different values of willingness to pay?” 
Development of mathematical model will provide necessary evidence required by decision 
makers in development of the screening guidelines for breast cancer in the country under 
consideration. The model we present is developed for breast cancer but has potential to 
produce evidence on cervical cancer and colorectal cancer with respective changes. 
Addressing issues in screening schedule development and reinforcing the decisions with 
evidence on breast cancer, colorectal cancer and cervical cancer (these three cancers being 
responsible for major proportion of burden) will significant help low and middle-income 
countries in managing the increasing burden due to cancer. 
Next section will discuss the developed method in detail followed by discussion and 
conclusion. 
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CHAPTER 5 
METHODOLOGY 
 
5.1 Approach 
 
 
Figure 1: Model structure 
 
The developed model has three main components, first is parameterization of the natural 
history of breast cancer, second is finite horizon Markov decision process model for 
computing optimal mammography schedules and finally a compartmental simulation 
model for simulating the screening schedules either computed from MDP model or the 
suggested screening guidelines from previous literature. These three models are arranged 
in series as shown in Figure 1, where second and the third model take input from the 
previous model and literature. Parametrization model, the first one, takes data input from 
GLOBOCAN 2012 database for age-specific incidence and mortality of breast cancer, 
literature and demographic projection software ‘Spectrum’. The literature input for the 
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parameterization model includes distribution of diagnosed cases over cancer stages, 
observed specifically in a country. For the optimization model, literature input includes 
cost and test specific parameters for mammography screening. Lastly, for the simulation 
model for outcomes and economic analysis, the literature input contains set of different 
policies observed in practice or mentioned in WHO guidelines. 
Following sections will discuss each block of the mathematical model, from 
parameterization to simulation model, in detail. 
5.2 Method 
 
5.2.1 Overview of breast cancer disease progression  
 
We assumed that breast cancer initiated first as carcinoma in-situ (CIS), i.e. women could 
transition from healthy to CIS.  In the absence of diagnosis, the disease naturally progresses 
through the invasive carcinoma preclinical stages local, regional, and distant, that we refer 
to as system states. From any of these preclinical disease states persons could transition to 
clinical states through diagnosis based on symptoms or through screening. Upon transition 
to a clinical state through diagnosis, persons remain in the state at diagnosis and face a 
certain rate of death based on treatment efficacy at the cancer stage at diagnosis. For 
persons who were diagnosed, we did not explicitly model recurrence of disease, we only 
applied an average stage-specific rate of survival. We present the flow diagram in Figure 
2. 
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Figure 2: Flow diagram of breast cancer onset and state progression 
 
We assumed that onset rates, i.e., the rate of transition from healthy to CIS, and diagnostic 
rates, i.e., the rates of transition from preclinical to clinical states, are dependent on the 
population under consideration and developed a two-step Markov process methodology for 
estimation of these rates.  We assumed rates of natural progression through cancer stages, 
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i.e., from preclinical CIS to local, to regional, and to distant, do not vary by geographical 
region and used pre-estimated rates from the literature. We present the data estimates taken 
from published literature in Appendix A.1. 
5.2.2 Two-Step Markov Process (TSMP) methodology for parametrization of the 
natural onset and progression of cancer 
 
The TSMP divides the estimation of population-specific onset rates of disease and 
diagnostic rates into two Markov process models, each defined over different state spaces. 
In the first step, we define the disease onset and progression as a discrete-time Markov 
process,  
𝑿 = {𝑋𝑡; 𝑡 ≥ 0, Ω, ℙ} (1) 
with a collapsed state space, 
Ω = {[𝐻𝑎], [𝑈𝑎], [𝐷𝑎]} 
Where, 
 𝑎 = 𝑎𝑔𝑒, and  
health states 𝐻𝑎 = Healthy, 𝑈𝑎 = Undiagnosed, and 𝐷𝑎 = Diagnosed, 
(see Figure 3 for a flow diagram, and Table 1: Overview of notations for the two-step 
Markov process parameterization methodology for a list of notations). 
 
Figure 3: Flow diagram for the collapsed states space in the first step of the Markov 
process parameterization 
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Table 1: Overview of notations for the two-step Markov process parameterization 
methodology 
𝐼𝑎 Incidence of cancer at age 𝑎, from GLOBOCAN 
𝐼?̅? Incidence of cancer at age 𝑎, from simulation model 
∆𝑡 time step in the simulation model 
𝜌𝑡 
steady state population in the state space 𝑍 (equation), from the 
simulation model, 
𝑑𝑖,𝑎 diagnostic rate of cancer in stage 𝑖 and age 𝑎, 
𝑠𝑗 percentage of diagnosed cases of cancer in the stage ‘j’ 
𝑝𝑖,𝑎 prevalence in pre-clinical state 𝑖 at age 𝑎 
𝜆𝑖 dwell rate for cancer stage 𝑖 
𝐼𝑖,𝑎 Incidence of cancer stage 𝑖 at age 𝑎  from GLOBOCAN data 
𝐼𝑖,𝑎̅̅ ̅̅  Incidence of cancer stage 𝑖 at age 𝑎  from, from simulation model 
 
clustering together all micro-states of the disease; and ℙ is the transition probability matrix. 
We estimate age-specific onset rates using an iterative analytical model derived using the 
Markov chain 𝑿. The technical details and proofs leading to the analytical model are 
presented in (27), here we only summarize the outline of the algorithm in  
Table 2: Algorithm for computing age-specific onset rate of cancer. 
 
Table 2: Algorithm for computing age-specific onset rate of cancer 
Initialize 𝜋𝐻0 = 𝐴0;  𝜋𝑈0 = 0; and 𝑃𝐻0𝑈0 = 0; Set 𝑎 = 1, the youngest age-group of cancer 
onset (we assumed age 15 for breast cancer).  
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Step 1: Calculate in-situ onset rate 
𝑃𝐻𝑎𝑈𝑎
=
𝐼𝐷𝑎𝑐𝑎 − ∑ (𝜋𝐻𝑘𝑃𝐻𝑘𝑈𝑘[∑ 𝑠𝑖(1 − 𝑒
−(𝑎−𝑘)𝜆𝑖)𝑖 − ∑ 𝑠𝑖(1 − 𝑒
−(𝑎−1−𝑘)𝜆𝑖)𝑖 ](∏ 𝑒
−𝜇𝑗
𝑗=𝑘:𝑎+1 ))
𝑎−1
𝑘=0
𝐴𝑎[∑ 𝑠𝑖(1 − 𝑒−𝜆𝑖)𝑖 ](𝑒−𝜇𝑎) − 𝐼𝐷𝑎𝑐𝑎
 
Where. 
1
𝜆𝑖
= ∑
1
𝑝𝑗
𝑖
𝑗=0 ; if 𝑝𝑗  are a function of age at disease onset then 
1
𝜆𝑖,𝑎
= ∑
1
𝑝𝑗,𝑎
𝑖
𝑗=0  
Then, disease onset rate at age 𝑎 is estimated as 
𝜃𝑎 = −ln (1 − 𝑃𝐻𝑎𝑈𝑎) 
Step 2: Calculate prevalence of healthy state: 
𝜋𝐻𝑎 =
𝐴𝑎 −∑ (𝜋𝐻𝑘𝑃𝐻𝑘𝑈𝑘𝑃(𝑇 ≥ 𝑎 − 𝑘)𝑃(𝑆 ≥ 𝑎 − 𝑘))
𝑎−1
𝑘=0  
1 + 𝑃𝐻𝑎𝑈𝑎
 
𝑃(𝑇 ≥ 𝑎 − 𝑘)𝑃(𝑆 ≥ 𝑎 − 𝑘) =  ∑𝑠𝑖(1 − 𝑒
−(𝑎−1−𝑘)𝜆𝑖)
𝑖
∏ 𝑒−𝜇𝑗
𝑗=𝑘:𝑎
 
Where, 
1
𝜆𝑖
= ∑
1
𝑝𝑗
𝑖
𝑗=0 ; if 𝑝𝑗  are a function of age at disease onset then 
1
𝜆𝑖,𝑎
= ∑
1
𝑝𝑗,𝑎
𝑖
𝑗=0  
Step 3: Increment 𝑎 by 1; if 𝑎 is less than the maximum age go to step 1, else stop. 
 
In the second step, we estimated diagnostic rates in each stage of cancer, i.e., 
transition rates from preclinical to clinical states (𝑑𝑖,𝑎), by using a simulation-based 
optimization method. In this method we simulate the Markov process 𝒀 = {𝑌𝑡; 𝑡 ≥
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0, 𝑍,ℚ}, where state space is 𝑍 = {[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎]}, and rate matrix ℚ, which 
corresponds to the  to the flow diagram in Figure 2. 
The objective of the simulation-based optimization model is to minimize the sum 
of square errors between the simulated cancer incidence (𝐼?̅?) and the GLOBOCAN 
predicted incidence (𝐼𝑎) (28). For completeness, we first present this earlier version of the 
model formulation before discussing the modifications specific to a data-limited setting 
that has partial screening programs. The objective function was formulated as 
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎 ∑ (𝐼?̅? − 𝐼𝑎)𝑎
2
, 𝑑𝑖,𝑎 ≥ 0, ∀𝑖, 𝑎       
 (2) 
As the analytical form of 𝐼?̅? are unknown, but the value of the objective function can be 
evaluated at different points of the decision parameters 𝑑𝑖,𝑎 ≥ 0, ∀𝑖, 𝑎, with simulation. 
Here, for any specific 𝑑𝑖,𝑎 values, we simulated the Markov Process 𝒀 over time 𝑡 using 
𝝆𝑡+1 = 𝝆𝑡 + 𝝆𝑡ℚ∆𝑡 until it reached state steady, i.e., 
𝝆 =  𝝆 +  𝝆ℚ∆𝑡         
 (3) 
where 𝝆 is a vector of state distribution at steady state and ℚ is the rate matrix.  
We estimated 𝐼?̅? using following equation, 
𝐼?̅? = ∑ 𝜌𝑈𝑖,𝑎 𝑑𝑖,𝑎𝑖 , 
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where 𝜌𝑈𝑖,𝑎 is the steady state value for state 𝑈𝑖,𝑎 (denoting the prevalence in pre-clinical 
cancer stage 𝑖 at age 𝑎), which can be estimated by expansion of equation (3) as 
𝜌𝑈𝑖,𝑎 = 𝜌𝑈𝑖,𝑎 + 𝜌𝑈𝑖−1,𝑎−1𝜆𝑖−1,𝑎 − 𝜌𝑈𝑖,𝑎−1 (𝜆𝑖,𝑎 + 𝑑𝑖,𝑎 + 𝜇𝑖,𝑎) 
 
 In the previously presented TSMP model in (27), because of the assumption that 
diagnosis is only symptomatic and that the probability of showing symptoms are higher in 
advanced disease stages, i.e., 𝑑𝑖,𝑎 > 𝑑𝑖−1,𝑎, the distribution of the stage at diagnosis was a 
good approximation for the ratio of stage-specific diagnostic rates. That is, 
𝑑𝑖,𝑎
𝑑3,𝑎
= ∑ 𝑠𝑗
𝑖
𝑗=0 , 
where 𝑠𝑗 is the proportion diagnosed in stage 𝑗, and 𝑑𝑖,𝑎 is the diagnostic rate at state 𝑖 and 
age 𝑎. Therefore, for the terms in the objective function in equation (2) we could write 
(𝐼?̅? − 𝐼𝑎)
2 = (∑ 𝜌𝑈𝑖,𝑎 𝑑𝑖,𝑎𝑖 − 𝐼𝑎)
2
= (∑ 𝜌𝑈𝑖,𝑎 (𝑑3,𝑎 ∑ 𝑠𝑗
𝑖
𝑗=0 )𝑖 − 𝐼𝑎)
2
≈  𝑓(𝑑3,𝑎)  (4) 
Therefore, the only unknown values in the objective function in equation (2) were the 
diagnostic rates in the last stage of cancer (𝑑3,𝑎), as the steady state values in the pre-
clinical states, 𝜌𝑈𝑖,𝑎, are estimated numerically from the simulation of the Markov model 
in equation (3) as discussed above. The resulting objective function was  
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑3,𝑎 ∑ (∑ 𝜌𝑈𝑖,𝑎 (𝑑3,𝑎 ∑ 𝑠𝑗
𝑖
𝑗=0 )𝑖 − 𝐼𝑎)
2
𝑎    
(5) 
and the decision variables 𝑑3,𝑎∀𝑎 were solved iteratively for each 𝑎. However, in 
the case of  countries such as Peru, certain populations have undergone screening based on 
recommendations and regional programs help in country prior to 2012 (the latest incidence 
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data available at the time of this work was for year 2012), and thus, the assumption 𝑑𝑖,𝑎 >
𝑑𝑖−1,𝑎 does not hold. Therefore, we modified the objective function in equation (5) to  
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎,∀𝑖,𝑎 ∑ (𝜌𝑈𝑖,𝑎 (𝑑𝑖,𝑎) − 𝐼𝑎)
2
𝑖,𝑎 , 𝑑𝑖,𝑎 ≥ 0 ∀𝑖, 𝑎 
(6) 
Thus, the number of decision variables (the unknown values) now increase to include 
diagnostic rates in all stages 𝑖 and ages 𝑎, i.e., 𝑑𝑖,𝑎∀𝑖, 𝑎. This creates a large number of 
decision variables. As the number of decision variables increases, ascertaining the 
convergence of a solution algorithm to the global optima becomes more challenging. We 
address this by showing below that the optimization problem in equation (6) is separable 
both on 𝑖 and 𝑎 and thus equation (6) can be converted to 𝑖𝑎 number of sub-problems. Each 
sub-problem can then be solved separately but iteratively for 𝑑𝑖,𝑎, iterating over each 
𝑖 and 𝑎 (see below). We further test for the convexity of each sub-problem (see Appendix 
A.2).  
Remark 1: We can rewrite equation (6) as,  
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎 (𝜌𝑈𝑖,𝑎 (𝑑𝑖,𝑎) − 𝐼𝑎)
2
, 𝑑𝑖,𝑎 ≥ 0      (7)  
for each combination of 𝑖, 𝑎  pair thus generating  𝑖𝑎 number of sub-problems. Each 
function can then be solved separately for 𝑑𝑖,𝑎 but iteratively over age 𝑎 starting from the 
youngest age and, within each age, iteratively over cancer state 𝑖 starting with the earliest 
disease state.   
Proof:  
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Using the expression for 𝜌𝑈𝑖,𝑎 , from the expansion of the Markov process in 
equation (3) discussed above, and multiplying by 𝑑𝑖,𝑎 we can write 
𝜌𝑈𝑖,𝑎 𝑑𝑖,𝑎 = [𝜌𝑈𝑖,𝑎 + 𝜌𝑈𝑖−1,𝑎−1𝜆𝑖−1,𝑎 − 𝜌𝑈𝑖,𝑎−1 (𝜆𝑖,𝑎 + 𝑑𝑖,𝑎 + 𝜇𝑖,𝑎)] 𝑑𝑖,𝑎  (8) 
In equation (8), for 𝑖 = 0 (the in-situ stage) 𝜆𝑖−1,𝑎−1 = 𝜃𝑎−1 the cancer onset rate, and for 
all other values of 𝑖 (i.e., local, regional, and distant stages) 𝜆𝑖−1,𝑎−1 are the progression 
rates (see Figure 2); and 𝜇𝑖,𝑎−1 are the mortality rates. Values for 𝜆𝑖−1,𝑎−1 and 𝜇𝑖,𝑎−1 are 
known. When 𝑖 = 0 (the in-situ stage) 𝜌𝑈𝑖−1,𝑎−1 = 𝜌𝐻𝑎−1denoting the steady state value in 
healthy (i.e., prevalence of healthy stage), and under all other values of 𝑖,  𝜌𝑈𝑖−1,𝑎−1 are the 
steady state values in the pre-clinical states (i.e., prevalence of pre-clinical cancer stages). 
For any given 𝑖, 𝑎 pair, from Remark 2 and its proof below, the steady state values for 
𝜌𝑈𝑖,𝑎−1 and 𝜌𝑈𝑖−1,𝑎−1, and solution to 𝑑𝑖,𝑎−1 are known.  Therefore, for any value of 𝑑𝑖,𝑎, the 
steady state value for 𝜌𝑈𝑖,𝑎  can be calculated through simulation of the Markov process in 
equation (3). As such, the only unknown value in equation (8) will then be 𝑑𝑖,𝑎 which can 
be solved by applying a non-linear solver to the optimization problem in equation (7). To 
identify convergence of the algorithm to global optima, we test for the convexity of 
equation (7), which we discuss in Appendix A.2. 
This completes the proof. 
Remark 2:  If we iteratively solve for 𝑑𝑖,𝑎 using equation (8) by iterating over 𝑎 and, within 
each 𝑎, iterate over 𝑖, then, for any given 𝑖, 𝑎 pair, the steady state values for 𝜌𝑈𝑖,𝑎−1 and 
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𝜌𝑈𝑖−1,𝑎−1, and the solution to 𝑑𝑖,𝑎−1 are known. Thus, the only unknown term in equation 
(8) is 𝑑𝑖,𝑎 
Proof: 
We prove this by applying mathematical induction on equation (8) 
For 𝑖 = 0, 𝑎 = 1, 
𝜌𝑈0,1 𝑑0,1 = [𝜌𝑈0,1 + 𝜌𝐻0𝜃1 − 𝜌𝑈0,0 (𝜆0,𝑎 + 𝑑0,𝑎 + 𝜇𝐻,𝑎)] 𝑑0,1 
Then, the only unknown value is 𝑑0,1 because 𝜌𝑈0,0 = 0 and 𝜌𝐻0 is the actual 
prevalence of healthy persons in age 0 (obtained from population demographics) as 
the first age for disease risk is 1, and all other parameters are known as discussed 
in proof of Remark 1. 
Assuming the proof holds for 𝑖 = 𝑚, 𝑎 = 1, 
for = 𝑚 + 1 , 𝑎 = 1 
𝜌𝑈𝑚+1,1 𝑑𝑚+1,1
= [𝜌𝑈𝑚+1,1 + 𝜌𝑈𝑚,0𝜆𝑚,1 − 𝜌𝑈𝑚+1,0 (𝜆𝑚+1,1 + 𝑑𝑚+1,1 + 𝜇𝑚+1,1)] 𝑑𝑚+1,1 
Then, the only unknown parameter is 𝑑𝑚+1,1 as 𝜌𝑈𝑚,0 = 0 and 𝜌𝑈𝑚+1,0 = 0 as 
the first age of disease risk is 1.  
For = 0 , 𝑎 = 2 
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𝜌𝑈0,2 𝑑0,2 = [𝜌𝑈0,2 + 𝜌𝐻1𝜃2 − 𝜌𝑈0,1 (𝜆𝑖,2 + 𝑑𝑖,2 + 𝜇𝑖,2)] 𝑑0,2 
Then, the only unknown parameter is 𝑑0,2 because 𝜌𝐻1 = 𝜌𝐻1 − 𝜌𝐻0(𝜃1 + 𝜇𝐻,1) 
can be estimated through steady state simulation of equation (3) and 𝜌𝑈0,1  was 
estimated previously under = 0 , 𝑎 = 1. 
Assuming the proof holds for 𝑖 = 𝑚, 𝑎 = 2, 
for = 𝑚 + 1 , 𝑎 = 2 
𝜌𝑈𝑚+1,2 𝑑𝑚+1,2
= [𝜌𝑈𝑚+1,2 + 𝜌𝑈𝑚,1𝜆𝑚,2 − 𝜌𝑈𝑚+1,1 (𝜆𝑚+1,2 + 𝑑𝑚+1,2 + 𝜇𝑚+1,2)] 𝑑𝑚+1,2 
Then, the only unknown parameter is 𝑑𝑚+1,2 as 𝜌𝑈𝑚,1 and 𝜌𝑈𝑚+1,1  were 
estimated above under = 𝑚 , 𝑎 = 1 and 𝑖 = 𝑚 + 1 , 𝑎 = 1, respectively 
Finally, assuming the proof holds for any 𝑖  and 𝑎 = 𝑘, 
for any 𝑖 , and 𝑎 = 𝑘 + 1 
𝜌𝑈𝑖,𝑘+1 𝑑𝑖,𝑘+1 = [𝜌𝑈𝑖,𝑘+1 + 𝜌𝑈𝑖−1,𝑘𝜆𝑖−1,𝑘+1 − 𝜌𝑈𝑖,𝑘 (𝜆𝑖,𝑘+1 + 𝑑𝑖,𝑘+1 + 𝜇𝑖,𝑘+1)] 𝑑𝑖,𝑘+1 
Then, the only unknown parameter is 𝑑𝑖,𝑘+1 as 𝜌𝑈𝑖−1,𝑘  and 𝜌𝑈𝑖,𝑘  were estimated 
above under any 𝑖and 𝑎 = 𝑘. 
This completes the proof. 
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Therefore, in this way we are first making the objective function fit for the setting of 
countries such as in Latin America, where diagnosis is not entirely symptomatic, i.e. 
changing the objective function from equation (5) to equation (6). By doing so, we are 
increasing the size of the problem as equation (6) does have 4 times more decision variables 
(𝑑𝑖,𝑎, , 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 = 400) than the equation (5) 
(𝑑4,𝑎, 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 = 100). Proving the separability of the objective 
function coverts the larger problem into 400 sub-problems, each having only one decision 
variable, if solved iteratively from earliest disease state and age. Figure 4, gives a visual 
representation of the optimization process, starting from earliest cancer state and age. 
 
 31 
 
Figure 4: Iterative process of solving sub-optimization problems for diagnosis rates 
 
5.2.3 A Markov decision process (MDP) to identify optimal screening intervals for 
mammography 
 
We formulated the problem of identifying an optimal screening strategy, specifically, 
what ages to screen, as a finite horizon MDP defined as {𝑋𝑠, 𝐷𝑠;  𝑍, 𝐴, ℙ𝑎, 𝑅𝑎} (see Table 
3: Overview of the notations used in the Markov decision process model for notations),  
Table 3: Overview of the notations used in the Markov decision process model 
ℙ Transition probability matrix 
𝐴 Action space 
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𝑍 {[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎]} 
𝑘 {[𝐻𝑎], [𝑈𝑖,𝑎]} 
𝑉(𝑖′, 𝑠, 𝑎) 
value function of the Bellman equation for state 𝑖′, at stage 𝑠, if action 
𝑎 is taken 
𝜋𝑖′  steady state distribution for state 𝑖
′ ∈ 𝑘 
𝑟(𝑖′, 𝑠, 𝑎) expected reward in state 𝑖′ and stage 𝑠, under action 𝑎 
𝑝(𝑖′, 𝑠, 𝑎, 𝑗) 
probability of transition from 𝑖′  to 𝑗 , at stage 𝑠, under action 𝑎 , where 
𝑗 ∈ 𝑍 
𝑎∗(𝑘, 𝑠) optimal action in state 𝑘 at stage 𝑠 
 
Where, 
 𝑠 = 1 𝑡𝑜 100 are the decision making stages, here representing individual ages, 
 𝑋𝑠𝜖Z is the disease state at stage 𝑠, defined over state space Z = {[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎],𝑀}, 
where [𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎] are healthy, preclinical, and clinical states as in the Markov 
process model, and 𝑀 denotes a mortality state, 
 𝐴 is the action space which is a set of possible decisions at stage 𝑠, 𝐴𝑖 =
{𝑆𝑐𝑟𝑒𝑒𝑛(1), 𝐷𝑜 𝑛𝑜𝑡 𝑆𝑐𝑟𝑒𝑒𝑛(0)}  ∀𝑖′ ∈ 𝑘 = {[𝐻𝑎], [𝑈𝑖,𝑎]}, 𝐴𝑖 =
{𝐷𝑜 𝑛𝑜𝑡ℎ𝑖𝑛𝑔}∀𝑖𝜖{[𝐷𝑖,𝑎],𝑀} 
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 𝐷𝑠𝜖𝐴 is the decision taken at stage 𝑠 (choosing from set 𝐴, a set of possible decision 
choices), 
 ℙ𝑎 is the transition probability matrix for action 𝑎, with each element 𝑝(𝑖
′, 𝑠, 𝑎, 𝑗) 
representing the probability of transitioning from state 𝑖′ to state 𝑗 if the system is in stage 
𝑠 and action 𝑎 is taken (expressions for transition probabilities are mentioned in Appendix 
A.4), and 𝑅𝑎 is the immediate reward for action 𝑎, with 𝑟(𝑖
′, 𝑠, 𝑎, 𝑗) representing each 
element of the matrix.  
The problem is then to solve for the optimal values of 𝐷𝑠. Use of MDP in this context is a 
well-studied problem (26) so we do not discuss further details of the methodology here. 
We only show the formulation of the problem in the context of identifying optimal 
screening guidelines for any country considering costs of screening and willingness to pay 
per quality-adjusted life-year saved.  
The above MDP was solved using dynamic programming. In this method, at every stage 𝑠 
(representing age) the model chooses to do nothing if 𝑖𝜖{[𝐷𝑖,𝑎],𝑀} and if 𝑖
′ ∈ 𝑘 = 
{[𝐻𝑎], [𝑈𝑖,𝑎]}, the model either chooses to screen or to not screen by calculating the ‘value’ 
of each action choice 𝑉(𝑖′, 𝑠, 𝑎), and selecting the action that resulted in the highest values 
as the optimal action 𝑎∗(𝑖′, 𝑠) for that specific disease state (𝑖′) and age (𝑠) combination, 
as follows. 
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𝑉(𝑖′, 𝑠, 𝑎) = ∑ (
𝜋𝑖′
∑ 𝜋𝑚𝑚∈ 𝑘
)
𝑖′∈ 𝑘
[∑𝑝(𝑖′, 𝑠, 𝑎, 𝑗)𝑟(𝑖′, 𝑠, 𝑎, 𝑗)
𝑗∈𝑍
+∑𝑝(𝑖′, 𝑠, 𝑎, 𝑗)𝐽∗(𝑖′, 𝑠 + 1)
𝑗∈𝑍
] 
 ∀𝑎 ∈ 𝐴, ∀ 𝑖′ ∈ 𝑘 = {[𝐻𝑎], [𝑈𝑖,𝑎]}, 
 
(9) 
𝑎∗(𝑖′, 𝑠) =  𝑎𝑟𝑔 𝑚𝑎𝑥𝑎∈𝐴  𝑉(𝑖
′, 𝑠, 𝑎) , ∀ 𝑖′ ∈ 𝑘 (10) 
𝐽∗(𝑖′, 𝑠) =  𝑟(𝑖′, 𝑠, 𝑎∗(𝑖′, 𝑠))  +  ∑𝑝(𝑖′, 𝑠, 𝑎∗(𝑖′, 𝑠), 𝑗)𝐽∗(𝑖′, 𝑠 + 1)
𝑗∈𝑍
 
(11) 
Note that with the above equations all 𝑖′ ∈ 𝑘 = {[𝐻𝑎], [𝑈𝑖,𝑎]}, will have the same optimal 
action, as {[𝑈𝑖,𝑎]} are unobservable states.  
We set, 
𝑟(𝑖′, 𝑎, 𝑠 = 𝑛𝑜 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔, 𝑗) =  
{
 
 
 
 
0, 𝑖𝑓 𝑗 𝑖𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 
𝑟𝐿𝑌. 𝑞𝑗 + 𝑐𝑑 + 𝑐𝑖, 𝑖𝑓𝑖
′ ∈ [𝑈𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈ [𝐷𝑖,𝑎]
𝑟𝐿𝑌. 𝑞𝑗 + 𝑐𝑡, 𝑖𝑓𝑖
′ ∈ [𝐷𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈ 𝑀
𝑟𝐿𝑌. 𝑞𝑗  𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
, and 
𝑟(𝑖′, 𝑎, 𝑠 = 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔, 𝑗) =  
{
 
 
 
 
0 𝑖𝑓 𝑗 𝑖𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦
𝑟𝐿𝑌. 𝑞𝑗  +  𝑐𝑑  +  𝑐𝑖, 𝑖𝑓 𝑖
′ ∈ [𝑈𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈ {[𝐷𝑖,𝑎]}
𝑟𝐿𝑌. 𝑞𝑗 + 𝑐𝑡, 𝑖𝑓𝑖
′ ∈ [𝐷𝑖,𝑎] 𝑎𝑛𝑑 𝑗 ∈ 𝑀
𝑟𝐿𝑌. 𝑞𝑗 + 𝑐𝑠 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 
where,  
𝑐𝑠 = − (𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦𝑎𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚 + (1 − 𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦𝑎)(𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚  +
𝑐−𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠)),  
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𝑐𝑑 = − (𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚  + 𝑐+𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠), 
𝑟𝐿𝑌 =    value-per-QALY lived,  
where, 
qj= QALY associated with state j, qj = {
1 if j = Ha
 0 if j = M
0 < qj < 1 otherwise
,  
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦𝑎 is the specificity of mammography at age a, 
𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚 is the unit cost of mammography per person,  
𝑐−𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 is the cost of follow-up diagnostic tests for a false positive (per person) 
𝑐+𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 is the cost of follow-up diagnostic tests for a true positive (per person) 
𝑐𝑖 is the initial treatment cost per person, and  
𝑐𝑡 is terminal treatment cost per person, which was applied at the final year of life for 
women who die from breast cancer.  
Values of the above-mentioned parameters are noted in Appendix A.3. 
5.2.4 Simulation Model 
 
5.2.4.1 Pseudocode for simulation 
 
The model described above will consider the cross-sectional data and will compute the 
optimal screening schedules for given value per QALY. To evaluate performance of such 
screening schedules or to compute the outcomes of the screening schedules, we have 
developed a simulation model. This simulation model is a compartmental simulation model 
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and it computes outcomes collected over 100 years of span screening schedule. Pseudocode 
for the simulation model is as follows, 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙𝑖𝑧𝑒 𝝆 𝑎𝑛𝑑 𝒍 
𝝆 ← 𝑧𝑒𝑟𝑜𝑠(|𝑍|, 𝑠𝑚𝑎𝑥) 
𝒍 ← 𝑧𝑒𝑟𝑜𝑠(|𝑍|, 1) 
𝑓𝑜𝑟 𝑎 = 1: 𝑠𝑚𝑎𝑥 
𝝆𝒔  ← 𝝅𝒔𝑨𝒔 
𝑓𝑜𝑟 𝑡 = 1: 𝑡𝑚𝑎𝑥 
𝑓𝑜𝑟 𝑠 = 𝑠𝑚𝑎𝑥: 2 
𝝆𝒔  ← 𝝆𝒔−𝟏𝑷(. , 𝒔 − 𝟏, . , 𝒂, . , 𝒔) 
 𝜌1,1 ← 𝑏𝑖𝑟𝑡ℎ𝑠 
 𝒍 ←  𝒍 + ∑ 𝝆𝒔𝑠  
 
Where, 
𝝆 is matrix of population in each state, i.e. total |𝑍|, and each age/stage, i.e. 𝑠𝑚𝑎𝑥, 
𝑠𝑚𝑎𝑥 is maximum value of age/stage, i.e. 100, 
𝑡𝑚𝑎𝑥 is horizon over which policy outcomes are calculated, i.e. 100  
𝒍 is life years lived in each state, i.e. 𝑍 = {[𝐻𝑎], [𝑈𝑖,𝑎], [𝐷𝑖,𝑎]}, 
𝝅𝒔 is stationary distribution over the state space 𝑍, when age/stage is ′𝑠′, 
𝑨𝒔 is population distribution over ages 
𝑷(. , 𝒔 − 𝟏, . , 𝒂, . , 𝒔) is transition probability matrix at stage/age ‘𝑠 − 1’ under action ‘a’ 
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5.2.4.2 Impact Metrics 
 
To measure the outcomes of screening schedules identified by our model, we consider two 
impact metrics, life-years-saved per 1000 women and false positives per 1000 women, 
defined as follows. 
Life years saved per 1000 women =
103(𝐿𝑝𝑜𝑙𝑖𝑐𝑦 − 𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒)
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒
𝑡𝑎𝑣𝑔⁄
 
False positives per 1000 women =
103𝑁𝐹𝑃
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒
𝑡𝑎𝑣𝑔⁄
 
Where, 
𝐿𝑝𝑜𝑙𝑖𝑐𝑦 = Life years lived in the intervention scenario (optimal screening strategy) over a 
100 year period,  
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒= Life years lived in the base-case (no screening) over a 100 year period,  
𝑡𝑎𝑣𝑔 = average life expectancy in  the country, thus,  
𝐿𝑝𝑜𝑙𝑖𝑐𝑦
𝑡𝑎𝑣𝑔
 is an approximation used for 
estimating the average number of women in the simulation. 
𝑁𝐹𝑃 is the total number of false positives over a 100-year period, 
The values used in this application are summarized in Appendix A.3. 
5.2.5 Model validation 
 
To validate the model results, we generated additional scenarios of biennial screening 
under multiple age groups to compare with results presented in the literature (Figure 3). 
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Our model estimations for life years saved per 1000 women under these different screening 
schedules compared well with results presented in (29) (see 
 
Figure 5: Model validation: Life years saved per 1000 women compared to current 
screening levels3).  
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Figure 5: Model validation: Life years saved per 1000 women compared to current 
screening levels  
(Model group abbreviations: D = Dana-Farber Cancer Institute; E = Erasmus Medical 
Center; G = Georgetown University; M = M.D. Anderson Cancer Center; S = Stanford 
University; W = University of Wisconsin) 
 
The results in (29), from six independent models, were based on simulations of screening 
in women born in 1960 in the United States representative of a screening naïve US 
population.  Model inputs for parameterization, including pre-screening incidence and 
stage at diagnosis distribution, and mammography screen specificity, sensitivity, and costs 
were based on (29) and are presented in Appendix A.5.   
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CHAPTER 6 
DISCUSSION AND CONCLUSIONS  
 
In summary, this thesis presents a new methodology for parameterization of cancer natural 
onset and progression for data limited settings such as in low and middle income countries, 
and an application of MDP model for estimating optimal number of screens and ages to 
screen under different constraints of WTP (numeric value assigned for each life year lived) 
or number of possible lifetime screens. Though the literature presents multiple Markov 
processes-based parameterization methodologies and MDP models for identifying 
screening options, most of these have been applied to or derived from application to 
populations in high income countries (HICs). As noted by other researchers in systematic 
reviews of economic evidence for informing breast cancer strategies for low and middle - 
income countries (LMICs), the quality of studies specific to LMICs are poor due to lack of 
data availabilities. (30) Countries thus adopt to extrapolating strategies or impacts of 
strategies from high-income countries, which can be challenging as clinical practices, 
health systems, infrastructure availabilities, and culture differ across countries.  
We believe the natural progression parameterization methodology presented here, that was 
specific to data availabilities in LMIC settings, addresses this key gap. This enables 
development of economic analysis that are more tailored to the country, by considering the 
population’s disease risk, resource availabilities, and preferences.  
Further, current WHO guidelines recommend prioritizing screening ages 50-69 and 
strongly recommends against screening for ages 40-49 in low resource settings even if 
health systems are relatively strong. The latter is mainly because of the increased number 
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of false positives, and increment in the risk of over treatment and over diagnosis due to 
false positives in ages 40-49, which require careful monitoring and evaluation that are 
usually not available in low resource settings.  
The above guidelines were based on RCTs and observational studies conducted in high 
income countries and supported by modeling studies. Conducting RCTs in every country 
is economically and practically infeasible. We believe, the method presented in this thesis, 
that integrates disease burden specific to a country into the modeling, can help evaluate 
evidence necessary to understand the risks and benefits of screening women under 
alternative strategies.  
To test and validate our model, we generated results for United States pre-screening 
incidence data and compared with previously presented results (29) (Appendix A.5). 
Results consisted of two outcome metrics, first life-years saved and false-positives, both of 
which are well matched with the results presented in Mandelblatt et.al. (29). 
Further, the optimal screening schedules and its impacts under multiple WTP assumptions 
or lifetime screen choices could help countries in planning current screening programs and 
their expansion in the future. For example, as the number of lifetime screenings can be 
related to infrastructural and resource needs, the scenario to adopt could be based on current 
or future resource/infrastructure capacities.  
The model is subject to limitations. We only considered heterogeneity by age for incidence 
and did not consider any other population characteristics or differences across countries. 
Causal factors for differences across countries in the risk of disease could be multiple, 
including diet, alcohol and tobacco consumption, competing diseases, or genetic. For 
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persons who were diagnosed, we did not explicitly model recurrence of disease, we only 
applied an average stage-and age specific rate of survival. We assumed that for persons 
with the disease, progression rates in preclinical stages do not vary by populations. The 
transition parameters were based on cancer stage, but we did not model heterogeneity in 
the cancer subtypes between different populations, or the family history of cancer. We did 
not model over-diagnosis of cancers, we only modeled age-specific false positives of 
mammography which were incorporated as costs in the MDP model. 
Despite these limitations, we believe the methodologies presented for breast cancer from 
this study, when applied to a low or middle income country, can have an impactful 
contribution to cancer control . We believe, our approach to analysis, of identifying optimal 
screening ages and intervals under alternate choices of number of lifetime screens, can help 
countries evaluate what options are feasible based on current screening capacities, and 
adopt the most cost-effective scenario from among the feasible choices. Further, as 
countries are developing an ‘investment case’ to scale-up infrastructure and strengthen 
health systems to achieve the goals of mortality reductions from NCDs, pledged under the 
Sustainable Development Goals and the WHO Global Action Plan, the method presented 
here could help decision-makers determine future infrastructure needs. We believe, the 
methodology presented here can be expanded to evaluate interventions in combination or 
interventions for other types of cancers, which can further help in the development of the 
broader investment case for the prevention of non-communicable diseases. 
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APPENDIX A 
DATA ASSUMPTIONS FOR PARAMETERIZATION OF CANCER ONSET AND 
PROGRESSION 
 
Table 4: Region specific input data for parameterization 
Parameters Value Reference 
GENERAL PROGRESSION PARAMETERS  (32) (33) (34) 
 
Progression rates 
 
 
 
In-situ to Local (𝜆0,𝑎 ) 0.19 
Local to Regional (𝜆1,𝑎) 0.33 
Regional to Distant (𝜆2,𝑎) 0.43 
 
Annual mortality rate (per person year) without 
treatment by stage at diagnosis 
 
 In-situ 0.08 
Local 0.14 
Regional 0.23 
Distant 0.50 
 
Annual mortality rate (per person year) with 
treatment by stage at diagnosis 
  
In-situ (μ1) 0.01  
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Local (μ2) 0.02  
Regional (μ3) 0.08  
Distant (μ4) 0.27  
 
REGION-SPECIFIC DATA 
  
 
Pre-screening incidence per 1000 persons per 
year 
 
(35) (36) 
 
Age group US 
0-14 0.00 
15-39 0.06 
40-44 1.09 
45-49 1.72 
50-54 1.97 
55-59 2.21 
60-64 2.60 
65-69 2.84 
70-74 3.06 
75-100 0.29 
 
Distribution of stage at diagnosis in base-case 
 
 
(37) (38) (39) (36) 
Stage  US 
In-Situ 4.70% 
 45 
Local 48.30% 
Regional 39.50% 
Distant 7.50% 
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APPENDIX B 
TEST FOR CONVEXITY OF THE OPTIMIZATION MODEL FOR 
ESTIMATION OF DIAGNOSTIC RATES 
 
In the main paper, diagnostic rates were estimated by solving for the optimization models  
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎(𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
, 𝑑𝑖,𝑎 ≥ 0 for each combination of cancer stage (𝑖) and age (𝑎)  
pair, where 𝐼?̅?,𝑎 and 𝐼𝑖,𝑎 are the simulated and actual cancer incidence in stage 𝑖 and age 𝑎, 
thus solving 𝑖𝑎 number of optimization models. To check for the convergence of the 
solution to global optima we test for the convexity of the objective functions. 
Specifically, we test for the commonly used convexity test, a function 𝑓(𝑥) that is twice 
differentiable on 𝑥 is convex if it is positive semi-definite, i.e., the second derivative 
𝑓′′(𝑥) ≥ 0 at all points of 𝑥. However, we do not know the analytical form of 𝐼?̅?,𝑎 to 
calculate the second derivative of the objective function (𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
. Therefore, for each 
combination of cancer stage (𝑖) and age (𝑎)  pair, we empirically generated the function 
for 𝐼?̅?,𝑎 by estimation at multiple points of 𝑑𝑖,𝑎. See Figure 1 and Figure 2 for results on In-
situ and Local stages of cancer and at multiple age groups. 
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Figure 6: Incidence vs diagnostic rate for specific age-group and In-situ stage of cancer 
  
  
Figure 7: Incidence vs diagnostic rate for specific age-group and local stage of cancer 
 
From the above empirical results, for any given cancer stage and age, the simulated 
incidence 𝐼?̅?,𝑎 is approximately a linear or a logarithmic function of diagnostic rates 𝑑𝑖,𝑎, 
i.e., 
𝐼?̅?,𝑎~𝑐 𝑙𝑛(𝑑𝑖,𝑎) + 𝑏 or 𝐼?̅?,𝑎~𝑐𝑑𝑖,𝑎 + 𝑏 for some constants 𝑐 and 𝑏. 
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Writing 𝑥 = 𝑑𝑖,𝑎, 
If 𝐼?̅?,𝑎~𝑐 𝑙𝑛(𝑥) + 𝑏 , the second derivative of the objective function (𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
on 𝑥 is 
𝑓′′(𝑥) =
𝑑2
𝑑𝑥2 
(𝑐 𝑙𝑛(𝑥) + 𝑏 − 𝐼𝑖,𝑎)
2
=
2(𝐼𝑖,𝑎−𝑏−𝑐 𝑙𝑛(𝑥)+𝑐)
𝑥2
> 0 as 𝐼𝑖,𝑎 > 𝑏 
And if 𝐼?̅?,𝑎~𝑐𝑥 + 𝑏, the second derivative of the objective function (𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
on 𝑥 is 
𝑓′′(𝑥) =
𝑑2
𝑑𝑥2 
(𝑐𝑥 + 𝑏 − 𝐼𝑖,𝑎)
2
= 2𝑐(𝑐) > 0 
thus, proving that the objective function (𝐼?̅?,𝑎 − 𝐼𝑖,𝑎)
2
 is convex 
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APPENDIX C 
ASSUMPTIONS FOR SCREENING PARAMETERS 
 
Table 5: Parameters specific to mammography 
Parameter name Assumption1 (40) (11) (41) (42) 
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 (Specificity of 
mammogram) for US 
Age Initial Annual Biennial Triennial 
<49 0.85356 0.91812 0.90472 .89606 
50-59 0.85576 0.91974 0.90498 .90013 
60-69 0.86576 0.92974 0.91459 .91013 
70-79 0.88384 0.93602 0.92127 .91974 
 
𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 (Sensitivity of 
mammogram) for US 
 
Age Initial Annual Biennial Triennial 
<49 0.87158 0.75644 0.81730 0.83026 
50-59 0.88126 0.77184 0.82155 0.83783 
60-69 0.90754 0.80298 0.85269 0.86897 
70-79 0.92611 0.84373 0.88126 0.89640 
𝐶𝑠𝑐𝑟𝑒𝑒𝑛 (Screening cost) for US 81.35 USD 
𝐶𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 (Cost of follow-up 
tests if diagnosed) for US 
Age group True positive, $ 
False positive, 
$ 
40–49 2187.89 1025 
50–64 2053.74 1425.48 
65–74 2065.13 1432.47 
≥75 1741.3 1509.49 
 
𝐶𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 (Cost of treatment 
by stage at diagnosis) for US 
Stage Initial, $ Terminal, $ 
In situ 13055 35335 
localized 13055 35335 
Regional 24682 41825 
Distant 38119 58665 
 
 
 
 
 
 
 
1 : Assumptions for cost parameters are taken from working paper 
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APPENDIX D 
TRANSITION PROBABILITY MATRICES 
 
Table 6: Notation used in transition probability matrix 
𝜃𝑖,𝑎 Onset rate of breast cancer 
𝜆𝑖,𝑎 Dwell rate for cancer stage 𝑖 and age 𝑎 
𝑑𝑖,𝑎 Diagnostic rate of cancer in stage 𝑖 and age 𝑎 
𝜇𝑎 Natural mortality rate at age 𝑎 
𝜇𝑖,𝑎̿̿ ̿̿̿ Diseased mortality in cancer stage 𝑖 and age 𝑎 
 
Table 7: Transition probability matrix for action = no screening 
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 52 
Table 8: Transition probability matrix for action = screening 
 53 
 
 54 
Where, 
?̅?𝑖,𝑎 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦)𝑑𝑖,𝑎 + 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦
− 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦(1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦)𝑑𝑖,𝑎 
?̅?𝑖,𝑎 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦)𝜆𝑖,𝑎 
𝑠 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦) 
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APPENDIX E 
MODEL VERIFICATION AND VALIDATION ON THE US POPULATIONS 
 
Verifying parameterization of natural history model for the US: 
 
Table 9: Age distribution of the incidence of the onset of preclinical breast cancer 
 
1. Age distribution of the incidence of the onset of preclinical breast cancer 
(including ductal carcinoma in situ). 
 
Age         US Study (43)           Our Model  
20 0.000 0.001 
25 0.002 0.003 
30 0.005 0.007 
35 0.021 0.019 
40 0.046 0.046 
45 0.105 0.099 
50 0.169 0.172 
55 0.233 0.258 
60 0.328 0.354 
65 0.436 0.457 
70 0.563 0.563 
75 0.707 0.670 
80 0.852 0.799 
85 1.000 1.000 
 
2. Compare estimated versus actual incidence at stage diagnosis distribution 
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Figure 8: Comparison of estimated versus actual incidence at stage diagnosis distribution for US 
 
3. Comparison of outcomes 
a. Life-Years saved 
 
Figure 9: Comparison of Life years saved for US from our model with that of six models 
developed within NCI and CISNET  
(Model group abbreviations: D = Dana-Farber Cancer Institute; E = Erasmus Medical Center; G 
= Georgetown University; M = M.D. Anderson Cancer Center; S = Stanford University; W = 
University of Wisconsin) 
 
b. False positive rate 
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Figure 10: Comparison of false positives for US from our model with that of six models 
developed within NCI and CISNET  
(x-axis abbreviations: A = Annual screening schedule in mentioned age-group, B = Biennial 
screening schedule in mentioned age-group) 
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